These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19465882)

  • 1. Second opinions improve ADHD prescribing in a medicaid-insured community population.
    Thompson JN; Varley CK; McClellan J; Hilt R; Lee T; Kwan AC; Lee T; Trupin E
    J Am Acad Child Adolesc Psychiatry; 2009 Jul; 48(7):740-748. PubMed ID: 19465882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
    Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
    Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.
    Daughton JM; Kratochvil CJ
    J Am Acad Child Adolesc Psychiatry; 2009 Mar; 48(3):240-248. PubMed ID: 19242289
    [No Abstract]   [Full Text] [Related]  

  • 5. Update on drugs for hyperactivity in childhood.
    Drug Ther Bull; 2007 May; 45(5):37-40. PubMed ID: 17536494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
    Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
    Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
    Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
    Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
    Barner JC; Khoza S; Oladapo A
    Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
    Prasad S; Arellano J; Steer C; Libretto SE
    Int J Clin Pract; 2009 Jul; 63(7):1031-40. PubMed ID: 19570121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder.
    Hazell P
    Australas Psychiatry; 2004 Dec; 12(4):369-75. PubMed ID: 15715810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [My child is so restless].
    Schlamp D
    MMW Fortschr Med; 2007 Mar; 149(10):39-40. PubMed ID: 17408047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
    Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
    J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
    Wietecha LA; Williams DW; Herbert M; Melmed RD; Greenbaum M; Schuh K
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):719-30. PubMed ID: 20035590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder.
    Aldridge AP; Kroutil LA; Cowell AJ; Reeves DB; Van Brunt DL
    Pharmacoeconomics; 2011 Jul; 29(7):621-35. PubMed ID: 21473655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
    Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
    Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Goto T; Takita Y; Chung SK; Wang Y; Gau SS
    Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.